Aligos Therapeutics (ALGS) Equity Average (2019 - 2026)

Aligos Therapeutics has reported Equity Average for 8 years, with the latest figure at $42.7 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average fell 2.44% year-over-year to $42.7 million; the trailing twelve-month figure through Mar 2026 stood at $42.7 million (down 2.44% YoY), and the FY2025 full-year result was $12.3 million, down 61.06% from the prior year.
• Equity Average for Q1 2026 stood at $42.7 million, down from $62.7 million in the prior quarter.
• The five-year high for Equity Average was $168.8 million in Q1 2022, with the low at $10.6 million in Q4 2024.
• Historically, Equity Average has averaged $83.4 million across 5 years, with a median of $75.9 million in 2024.
• Annual changes were most pronounced in 2024 — Equity Average slumped 85.62% — and 2025, when it jumped 493.56%.
• Aligos Therapeutics' Equity Average stood at $113.0 million in 2022, then tumbled by 34.97% to $73.5 million in 2023, then tumbled by 85.62% to $10.6 million in 2024, then jumped by 493.56% to $62.7 million in 2025, then slumped by 31.94% to $42.7 million in 2026.
• The last three Equity Average figures came in at $42.7 million (Q1 2026), $62.7 million (Q4 2025), and $86.8 million (Q3 2025), per Business Quant data.